Previous 10 | Next 10 |
2024-03-22 06:15:00 ET Breakthroughs in the biotech industry sometimes come from relatively small drugmakers. Competing with the largest companies in significantly crowded areas, such as oncology, can be difficult. That's why relatively unknown biotechs often opt to develop medicine where t...
2024-03-20 20:11:22 ET Summary Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024. In a prior phase 2 study, it was shown that Belapectin was effective in treating patients w...
2024-03-19 19:52:33 ET Summary John Paulson's 13F portfolio value decreased slightly from $1.12B to $1.11B in the last quarter. The top five positions in Paulson's portfolio are Madrigal Pharma, Bausch Health, Brightsphere Investment Group, NovaGold, and Perpetua Resources. Pa...
2024-03-19 05:50:00 ET Every huge drugmaker was once a much smaller drugmaker. We don't even have to go back too many years to see where Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) , currently the two biggest pharma companies on the planet, were only a fraction of the...
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of i...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
2024-03-18 16:38:49 ET Gainers: National CineMedia ( NCMI ) +8% . Inventiva ( IVA ) +6% . Alpine Immune Sciences ( ALPN ) +5% . Leslie's ( LESL ) +5% . Maxeon Solar Technologies ( MAXN ) +5% . Losers: DLocal ( DLO...
2024-03-18 16:12:11 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
2024-03-18 10:15:15 ET Summary On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra ...
2024-03-17 05:50:00 ET Some events are so pivotal for a company that they cause everything to change. The company's world instantly becomes brighter -- or darker. Madrigal Pharmaceuticals (NASDAQ: MDGL) just experienced such an event. Last Thursday, the company won U.S. Food and...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...